Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.22.2
Commitments and Contingencies (Details)
$ in Millions
1 Months Ended
Jun. 15, 2012
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Milestone payment $ 1
Description of royalty payment Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.